Acceleron, Shire deal

Acceleron granted Shire exclusive rights outside North America to its molecules targeting the activin receptor type 2b (ACVR2B) pathway. The deal includes ACE-031, a myostatin (GDF8) inhibitor in Phase IIa testing to treat Duchenne muscular dystrophy (DMD), plus other molecules for muscular and neuromuscular disorders. Acceleron will receive $45 million up front and is eligible for up to $453 million in milestones, plus royalties. ...